LONDON — The U.K.-based drugmaker GSK said early Wednesday that it planned to invest $30 billion in the U.S. over five years, an announcement timed to this week’s state visit here by President Trump.
The company, which said the funds would be used to expand research and manufacturing operations and build out AI capabilities, is the latest drugmaker to unveil major investments in the U.S. since the start of the Trump administration, following the likes of Eli Lilly, AstraZeneca, Novartis, and others.
Advertisement
With Trump in the U.K., GSK touts $30 billion investment in U.S. over 5 years
RELATED ARTICLES
